4: Statement of changes in beneficial ownership of securities

• Post author:andrewkaretas
• Post published:November 19, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading4: Statement of changes in beneficial ownership of securities

144: Filed by “insiders” prior intended sale of restricted stock.

• Post author:andrewkaretas
• Post published:November 17, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading144: Filed by “insiders” prior intended sale of restricted stock.

SCHEDULE 13G/A: SCHEDULE 13G/A – Description

• Post author:andrewkaretas
• Post published:November 13, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingSCHEDULE 13G/A: SCHEDULE 13G/A – Description

SCHEDULE 13G/A: SCHEDULE 13G/A – Description

• Post author:andrewkaretas
• Post published:November 13, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingSCHEDULE 13G/A: SCHEDULE 13G/A – Description

SCHEDULE 13G/A: SCHEDULE 13G/A – Description

• Post author:andrewkaretas
• Post published:November 12, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingSCHEDULE 13G/A: SCHEDULE 13G/A – Description

December 2, 2025 12:00 PM EST : Piper Sandler 37th Annual Healthcare Conference

• Post author:andrewkaretas
• Post published:November 10, 2025
• Post category:Events

Continue ReadingDecember 2, 2025 12:00 PM EST : Piper Sandler 37th Annual Healthcare Conference

November 18, 2025 5:00 AM EST : Jefferies Global Healthcare Conference in London

• Post author:andrewkaretas
• Post published:November 10, 2025
• Post category:Events

Continue ReadingNovember 18, 2025 5:00 AM EST : Jefferies Global Healthcare Conference in London

November 12, 2025 4:30 PM EST : TD Cowen’s Immunology & Inflammation Virtual Summit

• Post author:andrewkaretas
• Post published:November 10, 2025
• Post category:Events

Continue ReadingNovember 12, 2025 4:30 PM EST : TD Cowen’s Immunology & Inflammation Virtual Summit

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

• Post author:andrewkaretas
• Post published:November 10, 2025
• Post category:Latest News

SOUTH SAN FRANCISCO, Calif. , Nov. 10, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…

Continue ReadingAllogene Therapeutics Announces Participation in Upcoming Investor Conferences

10-Q: Quarterly report which provides a continuing view of a company’s financial position

• Post author:andrewkaretas
• Post published:November 6, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading10-Q: Quarterly report which provides a continuing view of a company’s financial position